Abstract
Purpose: To assess the prognostic value of systemic immune-inflammation index (SII) for disease progression in locally advanced renal cell carcinoma (RCC). Materials and methods: A total of 97 patients with locally advanced RCC who underwent curative surgery between January 1, 2010 and December 31, 2018 were included in this retrospective study. The study was approved by the Institutional Review Board of Linkou Chang Gung Memorial Hospital with an IRB number of 202000092B0. Outcomes analyzed were the disease-free survival (DFS) of patients with locally advanced RCC and the prognostic value of SII. Results: Among 97 locally advanced RCC patients, disease progression was noted in 48.5% of the patients. The median DFS was 55.6 months (95% confidence interval: 45.1–66.2 months). An elevated SII greater or equal to 514 was associated with a poorer DFS. After multivariate analyses of possible predictive factors, SII remained statistically associated with a poorer DFS. Conclusion: An elevated SII was associated with a poorer DFS in patients with locally advanced RCC. SII could be used as a prognostic factor to guide the use of adjuvant therapy after curative surgery for patients with locally advanced RCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
